We just released a new video update, and if you’re wondering how Cytonics is challenging Big Pharma — and what makes CYT-108 different — this is the one to watch.
In under five minutes, CEO Joey Bose breaks down:
- The true cause of osteoarthritis (hint: it’s not just inflammation)
- Why our first-gen therapy, APIC, helped 10,000+ patients — and what we learned from it
- How CYT-108, our engineered A2M drug, is designed to target the root of joint damage, not just symptoms
- The science, the strategy, and what’s next in the clinic
If you want to understand the mission, the molecule, and the opportunity — this video delivers.
And if you’re ready to back a company built on results, not promises:
Appreciatively,
Joey Bose
President & CEO
Reg A Disclaimer
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. You may obtain a copy of the offering circular here.
